295 related articles for article (PubMed ID: 27976465)
1. Determination of the Nail Psoriasis Severity Index improvement rate standards for nail psoriasis treatment in a phase IV clinical trial of ustekinumab: the MARCOPOLO study.
Youn SW; Kim BR; Cho S; Seo SJ; Lee ES; Roh JY; Choi GS; Lee MG;
J Eur Acad Dermatol Venereol; 2017 Jun; 31(6):e298-e299. PubMed ID: 27976465
[No Abstract] [Full Text] [Related]
2. Efficacy of ustekinumab in nail psoriasis and improvement in nail-associated quality of life in a population treated with ustekinumab for cutaneous psoriasis: an open prospective unblinded study.
Rigopoulos D; Gregoriou S; Makris M; Ioannides D
Dermatology; 2011; 223(4):325-9. PubMed ID: 22134046
[TBL] [Abstract][Full Text] [Related]
3. Dermoscopic features of nail psoriasis treated with biologics.
Hashimoto Y; Uyama M; Takada Y; Yoshida K; Ishiko A
J Dermatol; 2017 May; 44(5):538-541. PubMed ID: 28150346
[TBL] [Abstract][Full Text] [Related]
4. Ustekinumab improves nail disease in patients with moderate-to-severe psoriasis: results from PHOENIX 1.
Rich P; Bourcier M; Sofen H; Fakharzadeh S; Wasfi Y; Wang Y; Kerkmann U; Ghislain PD; Poulin Y;
Br J Dermatol; 2014 Feb; 170(2):398-407. PubMed ID: 24117389
[TBL] [Abstract][Full Text] [Related]
5. Comparison of NAPSI and N-NAIL for evaluation of fingernail psoriasis in patients with moderate-to-severe plaque psoriasis treated using ustekinumab.
Kim BR; Yang S; Choi CW; Youn SW
J Dermatolog Treat; 2019 Mar; 30(2):123-128. PubMed ID: 29757042
[TBL] [Abstract][Full Text] [Related]
6. Treatment of nail psoriasis with TNF-α or IL12/23 inhibitors.
Jemec GB; Ibler KS
J Drugs Dermatol; 2012 Aug; 11(8):939-42. PubMed ID: 22859238
[TBL] [Abstract][Full Text] [Related]
7. Treatment of psoriasis and psoriatic arthritis with secukinumab after unsatisfactory response to ustekinumab in multiple sclerosis patient.
Assefa GT; Kaneko S; Oguro H; Morita E
J Dermatol; 2019 Mar; 46(3):e112-e113. PubMed ID: 30151838
[No Abstract] [Full Text] [Related]
8. Successful treatment of ustekinumab in a severe psoriasis patient with human immunodeficiency virus infection.
Saeki H; Ito T; Hayashi M; Fukuchi O; Umezawa Y; Nobeyama Y; Teruya K; Nakagawa H
J Eur Acad Dermatol Venereol; 2015 Aug; 29(8):1653-5. PubMed ID: 24754476
[No Abstract] [Full Text] [Related]
9. Erythrodermic psoriasis treated with ustekinumab: an Italian multicenter retrospective analysis.
Pescitelli L; Dini V; Gisondi P; Loconsole F; Piaserico S; Piccirillo A; Stinco G; Errichetti E; Talamonti M; Tripo L; Volpi W; Prignano F
J Dermatol Sci; 2015 May; 78(2):149-51. PubMed ID: 25681953
[No Abstract] [Full Text] [Related]
10. Safety of ustekinumab in severe psoriasis with chronic hepatitis B.
Raymundo AR; Facin AP; Silva de Castro CC; Faria AR
Indian J Dermatol Venereol Leprol; 2016; 82(3):326-8. PubMed ID: 27088944
[No Abstract] [Full Text] [Related]
11. Psoriasis-associated interstitial pneumonia.
Hara H; Kuwano K; Kawamoto H; Nakagawa H
Eur J Dermatol; 2018 Jun; 28(3):395-396. PubMed ID: 29521628
[No Abstract] [Full Text] [Related]
12. Successful treatment of psoriatic crumbly nails with ustekinumab.
Galluzzo M; D'Adamio S; Chimenti MS; Teoli M; Bianchi L; Talamonti M
Dermatol Ther; 2019 May; 32(3):e12914. PubMed ID: 30968520
[TBL] [Abstract][Full Text] [Related]
13. Risankizumab versus ustekinumab for moderate-to-severe plaque psoriasis.
Fioranelli M; Roccia MG; Lotti T
Dermatol Ther; 2017 Sep; 30(5):. PubMed ID: 28508536
[No Abstract] [Full Text] [Related]
14. Interventions for nail psoriasis.
de Vries AC; Bogaards NA; Hooft L; Velema M; Pasch M; Lebwohl M; Spuls PI
Cochrane Database Syst Rev; 2013 Jan; (1):CD007633. PubMed ID: 23440816
[TBL] [Abstract][Full Text] [Related]
15. Treatment of nail psoriasis: best practice recommendations from the Medical Board of the National Psoriasis Foundation.
Crowley JJ; Weinberg JM; Wu JJ; Robertson AD; Van Voorhees AS;
JAMA Dermatol; 2015 Jan; 151(1):87-94. PubMed ID: 25471223
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of ixekizumab on nail psoriasis in paediatric patients with moderate-to-severe psoriasis: a post hoc analysis from IXORA-PEDS.
Seyger MMB; Reich A; El Baou C; Schuster C; Riedl E; Paller AS
J Eur Acad Dermatol Venereol; 2021 Dec; 35(12):e911-e913. PubMed ID: 34320259
[No Abstract] [Full Text] [Related]
17. A 36-week retrospective open trial comparing the efficacy of biological therapies in nail psoriasis.
Bardazzi F; Antonucci VA; Tengattini V; Odorici G; Balestri R; Patrizi A
J Dtsch Dermatol Ges; 2013 Nov; 11(11):1065-70. PubMed ID: 24119121
[TBL] [Abstract][Full Text] [Related]
18. Biologics in nail psoriasis.
de Berker D
Br J Dermatol; 2014 Feb; 170(2):236-7. PubMed ID: 24547718
[No Abstract] [Full Text] [Related]
19. Ustekinumab for the treatment of moderate-to-severe plaque psoriasis in a solid organ transplanted recipient: A case report.
Richetta A; Marraffa F; Grassi S; Aquila E; Dybala A; Aprile F; Merli M
Australas J Dermatol; 2021 Aug; 62(3):e442-e443. PubMed ID: 33634474
[No Abstract] [Full Text] [Related]
20. Efficacy and safety of ustekinumab in a group of 22 elderly patients with psoriasis over a 2-year period.
Megna M; Napolitano M; Balato N; Monfrecola G; Villani A; Ayala F; Balato A
Clin Exp Dermatol; 2016 Jul; 41(5):564-6. PubMed ID: 27028505
[No Abstract] [Full Text] [Related]
[Next] [New Search]
